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Abstract 
Objective: To document prostate cancer patient reported ‘ever experienced’ and ‘current’ 
prevalence of disease specific physical symptoms stratified by primary treatment received. 
Patients: 3,348 prostate cancer survivors 2-15 years post diagnosis. 
Methods: Cross-sectional, postal survey of 6,559 survivors diagnosed 2-15 years ago with 
primary, invasive PCa (ICD10-C61) identified via national, population based cancer registries 
in Northern Ireland and Republic of Ireland.  Questions included symptoms at diagnosis, 
primary treatments and physical symptoms (impotence/urinary incontinence/bowel 
problems/breast changes/loss of libido/hot flashes/fatigue) experienced ‘ever’ and at 
questionnaire completion (“current”). Symptom proportions were weighted by age, country 
and time since diagnosis.  Bonferroni corrections were applied for multiple comparisons. 
Results: Adjusted response rate 54%; 75% reported at least one ‘current’ physical symptom 
(‘ever’:90%), with 29% reporting at least three.  Prevalence varied by treatment; overall 57% 
reported current impotence; this was highest following radical prostatectomy (RP)76% 
followed by external beam radiotherapy with concurrent hormone therapy (HT); 64%.   
Urinary incontinence (overall ‘current’ 16%) was highest following RP (‘current’28%, 
‘ever’70%). While 42% of brachytherapy patients reported no ‘current’ symptoms; 43% 
reported ‘current’ impotence and 8% ‘current’ incontinence. ‘Current’ hot flashes (41%), 
breast changes (18%) and fatigue (28%) were reported more often by patients on HT.  
Conclusion: Symptoms following prostate cancer are common, often multiple, persist long-
term and vary by treatment.  They represent a significant health burden. An estimated 1.6% A
cc
ep
te
d 
A
rti
cl
e
 
 
This article is protected by copyright. All rights reserved. 
This is an open access article under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs License, which permits use and 
distribution in any medium, provided the original work is properly cited, 
the use is non-commercial and no modifications or adaptations are made. 
of men over 45 is a prostate cancer survivor currently experiencing an adverse physical 
symptom. Recognition and treatment of physical symptoms should be prioritised in patient 
follow-up. This information should facilitate men and clinicians when deciding about 
treatment as differences in survival between radical treatments is minimal. 
Keys words:  Prostate Cancer, Population, Patient Reported Outcomes 
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Introduction 
Prostate cancer (PCa), the most common cancer in males in developed countries, has an 
estimated 900,000 new cases  annually, 325,000  of which occur in Europe.[1]  Driven by 
ageing populations, widespread PSA testing and improved survival, PCa prevalence is 
predicted to rise in the UK from an estimated 255,000 in 2010 to 831,000 cases by 2040.[2] 
In Ireland, PCa currently accounts for 34% of male cancer survivors (excluding non-
melanoma skin cancers) in Northern Ireland (NI) and approximately 40% in the Republic of 
Ireland (RoI).[3-5]   
 
All PCa treatments carry the potential for adverse effects including impotence, 
incontinence, bowel problems, hot flashes and fatigue.[6]  Since studies have not 
conclusively shown survival benefits of one treatment over another for localised PCa robust 
population based estimates of prevalence and duration of symptoms post-treatment are 
valuable for informing treatment decision-making. [7-12] 
 
The majority of studies on side effects to date are from clinical trials which do not compare 
all treatment modalities, exclude older men and do not extend beyond 10 years.[13-16]  Our 
aim was to investigate the prevalence of physical symptoms that were ‘ever’ experienced  
and are ‘currently’ experienced at a population level, assess burden and inform policy to 
support medium to long term PCa survivors.  
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Patients and Methods 
The study took place on the island of Ireland.  Northern Ireland (NI) has a predominantly 
publically-funded health care system, whereas the Republic of Ireland (RoI) has a mixture of 
public and private health care.  The same approach was used in both settings to identify and 
recruit participants.  All men diagnosed with invasive PCa (ICD10 C61) between 1/1/1995 
and 31/03/2010 and alive at 31st March 2011 were identified through population based 
cancer registries (NI=5,519; RoI=17,304).  A random sample of survivors was screened for 
eligibility by healthcare providers (n=12,322, 52% of total sampling frame). Eligible survivors 
were: aware of their diagnosis; English speaking; resident in either NI or RoI; and well 
enough to complete a questionnaire (in particular had no cognitive impairment).  
 
In NI, eligibility was checked by research nurses, or the patient’s general practitioner (GP).  
In RoI, the patient’s GP confirmed eligibility.  In both areas, survivors whose eligibility was 
not confirmed e.g. GP non-response, were excluded. Following this process, 6,559 (53% of 
the random sample) were deemed eligible for invitation to complete a postal questionnaire 
(Figure I).   
 
A questionnaire including the EORTC QLQ C30, PR25, EQ5D-5L, DASS 21 and Decisional 
Regret Scale was developed following literature review with clinician and patient input.[17-
21] Questions included socio-demographic characteristics and pre-diagnosis symptoms 
(urinary problems [increased frequency, pain urinating, blood in urine], bowel problems 
[diarrhoea, constipation], and/or sexual dysfunction - impotence and loss of libido).  
Information on the latter two were requested ‘ever’ after treatment, ‘currently’ at A
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questionnaire completion and pre-diagnosis.  A list of PCa treatment modalities was 
included and survivors were asked to indicate all treatments received, with dates.  Specific 
questions were asked about seven potential disease or treatment related symptoms at two 
time points; ‘ever’ (i.e. anytime since treatment) and ‘current’ (i.e. at time of questionnaire 
completion). The symptoms considered were urinary incontinence, impotence, loss of 
libido, bowel problems, breast changes, hot flashes and fatigue. 
 
The draft questionnaire was pre-tested among 32 PCa survivors for acceptability, ease of 
understanding and face validity and modified accordingly.  Questionnaires were dispatched 
between April-September 2012.  Each man received a cover letter, information sheet, 
consent form and freepost return envelope with their questionnaire. Non-responders 
received up to two written reminders. Date of diagnosis, clinical stage and Gleason grade 
(GG) at diagnosis were extracted from cancer registry databases.  GG is collected and 
categorised as low (<5), medium (6-7) and high (>8) and not as raw data by the registry.  
Additional information was sourced for staging/GG for NI responders as these data were 
incomplete in routine data for earlier years.  
 
For survivors who answered some treatment or physical symptom questions, but omitted 
others from that section, a “no” response was assumed. Non-response to all of 5 treatment 
questions (3%, n=93), or all 14 symptom questions (3%, N=102), were coded as “missing” 
but retained in analyses.  
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To investigate whether symptoms varied by time since diagnosis, respondents were 
categorised into three groups: 2-4.9 years, 5-9.9 years and ≥10 years post-diagnosis. To 
study symptoms by treatment, a variable was created based on a mutually exclusive 
hierarchy of treatments: each man was categorised once based on primary treatment(s) 
received:   RP = Radical Prostatectomy at any time following diagnosis (with or without 
other treatments); EBRT with HT = External Beam Radiotherapy with concurrent hormone 
therapy within six months; EBRT without HT = External Beam Radiotherapy without 
concurrent HT; BT= Brachytherapy, excluding survivors with previous EBRT or RP; HT = 
Hormone Therapy alone without radical prostatectomy, external beam radiotherapy or 
brachytherapy; CT = Chemotherapy alone; MON = Monitoring including active surveillance 
or watchful waiting. 
 
Survivors were also categorised as: 1) currently on HT 2) previously received HT  and 3) 
never had HT.  Pre and post treatment experience was compared for loss of libido and 
impotence. 
 
Comparisons of symptom proportions across treatment groups were tested for significance 
at the 5% level using two-sided z-tests based upon weighted counts rounded to the nearest 
whole number, with differences in overall distributions tested using chi-square tests. 
Bonferroni corrections were applied to account for multiple comparisons. The Clopper 
Pearson interval method was used to generate exact 95% binomial confidence intervals for 
weighted proportion estimates. [22] 
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To extrapolate results to the entire PCa survivor population, weighted proportions of 
symptoms were computed.  Respondents’ characteristics were compared with those of all 
PCa survivors in Ireland (i.e. the total sampling frame) and the proportions with each 
symptom was adjusted with weights based on country, age at diagnosis and time since 
diagnosis.  
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Results  
In total 3,348 men responded, representing a 54% response rate after adjusting for 
eligibility following questionnaire dispatch. Respondents’ average age was 64·9 years 
(standard deviation 7·6). Compared to all PCa survivors, respondents were younger at 
diagnosis (χ2=49·6; p<0·001), diagnosed more recently (χ2=164·8; p<0·001), had their cancer  
staged (χ2= 673·0; p<0·001) and graded (χ2=653·1; p<0·001) (Table 1). Two thirds of 
respondents (64%) had presented with early disease (stage I/II), while 65% had an 
intermediate Gleason grade (5-7) at diagnosis. Almost half, 48%, were surveyed 2-4·9 years 
post-diagnosis, 32% were 5-9·9 years and 20% ≥10 years.  Those in the ≥10 year group were 
younger at diagnosis, less often had stage I/II disease and more often had low-grade disease 
compared with those diagnosed more recently (all comparisons p<0·001). They also more 
often reported RP treatment and less often BT or EBRT with HT (all comparisons p<0·001).  
At diagnosis over half (51.2%) of men reported urinary frequency, 18.8% impotence and 
14.7% loss of libido.  There were no significant variations in pre-treatment symptoms 
reported between groups diagnosed at different time periods (Table 2).  The responder’s 
treatment categories were compared with data from both cancer registries taken in 2001.  
The levels of chemotherapy (2% responders, 1.4% registry [p=0.11]), hormone therapy (45% 
responders, 44% registry[p=0.46]) and radical prostatectomy (27% responders, 38% registry 
[<0.01]) were within the range of the overall prostate cancer population.  The levels of 
radiotherapy were higher among responders at 58%, 24% registry [<0.01], in keeping with 
but not completely explained by increased use over time (RoI average 41% for 2007-2011). 
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‘Ever had’ physical symptoms: (weighted proportions)  
Overall, 90% of respondents, reported ‘ever’ experiencing at least one of the seven possible  
physical symptoms investigated post-treatment, 61% reported at least three, 20% four, one 
in eight (12.5%) reported five, 6% reported 6 and 2% reported all seven symptoms. Most 
common were impotence (68%), loss of libido (58%) and fatigue (55%).  There was 
significant variation in “ever” had symptoms by time since diagnosis.   Loss of libido was 
more common in men 2-4·9 years since diagnosis compared to those ≥10 years post-
diagnosis (60% vs 54%, respectively, p=0·010). Bowel problems (26% of all respondents) and 
fatigue (55% of all respondents) were less common among those ≥10 years post-diagnosis 
compared to other diagnosis periods, bowel (2-4·9 years, p<0·001; 5-9·9 years, p=0·004), 
fatigue (2-4·9 years, p<0·001; 5-9·9 years, p=0·007) (Table 3). 
‘Current’ physical symptoms: (weighted proportions)  
Three-quarters reported at least one ‘current’ symptom with 29% reporting three or more, 
and 4% at least five. 65% reported currently having impotence, urinary incontinence and/or 
bowel problems, and 57% reported at least one of the following; loss of libido, breast 
changes, fatigue or hot flashes (Figures 2a and 2b). There was no significant difference in 
proportions of ‘current’ symptoms between groups diagnosed during different periods.  For 
each symptom, ‘current’ proportions were lower than ‘ever’. The biggest differences were 
for fatigue (ever, 55%; current, 22%), hot flashes (39%, 6%) and urinary incontinence (37%, 
16%), and the smallest for impotence (68% vs 57%).  One quarter of survivors (25%) 
reported no ‘current’ physical symptoms (Table 3).   A
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Pre-and Post-treatment comparisons: 
Pre- and post-treatment comparisons were possible for impotence and loss of libido. Prior 
to diagnosis, 19% reported impotence, increasing with age at diagnosis from 16% of those 
<60 years, to 21% of men aged >70 years. Impotence as a new current symptom post-
treatment was reported by 43%, while 5% reported impotence pre-treatment, but not 
currently. This varied by primary treatment being highest following prostatectomy. Loss of 
libido was reported pre-diagnosis by 15% of survivors; 5% reported this pre-treatment but 
not currently; and 46% report ‘current’ loss of libido but not pre-treatment (Figure 3).  
 
Variations in ‘current’ physical symptoms by primary treatment:  
Among men treated with RP proportions of ‘current’ impotence (76%) and urinary 
incontinence (28%) were higher than the average for all respondents (weighted proportions; 
p<0·001) while bowel problems (9%), hot flashes (7%) and breast changes (3%) post-RP 
were lower than average (p<0·001 for all three comparisons).  
 
Men treated with EBRT with concurrent HT reported the highest proportions of current 
bowel problems (20%) compared to HT (9%), RP (9%), BT (7%) or MON (2%).  Survivors 
treated by EBRT with concurrent HT, compared to those who had  EBRT without concurrent 
HT, reported more ‘current’ loss of libido (58% vs 43%, p<0.001), impotence (64% vs 50%, 
p<0·001), breast changes (20% vs 9%, p<0·001), hot flashes (28% vs 15%, p<0·001) and 
fatigue (32% vs 23%, p<0·001). 
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Those treated with BT reported lower than average proportions of ‘current’ impotence 
(43%), loss of libido (26%), hot flashes (2%), and breast changes (2%); 42% of this group 
reported no ‘current’ problems. 
 
Men treated with HT alone reported high proportions of ‘current’ loss of libido (52%), 
impotence (51%), hot flashes (41%) and fatigue (28%); while 20% reported no ‘current’ 
physical symptoms. 
 
64% of men on monitoring reported no ‘current’ physical symptoms, higher than other 
groups (p<0·001). One in five men on monitoring reported loss of libido or impotence (21%), 
(only slightly higher than pre-treatment average levels - 19%), loss of libido (22%), other 
symptoms were less common in the monitoring group (urinary incontinence (7%), hot 
flashes (4%), fatigue (4%), bowel problems (2%) and breast changes (2%) (Table 3). 
 
Variation in ‘current’ symptoms by hormone therapy: 
Overall 45% reported receiving HT at some point post-diagnosis.  Current use of HT (19%) 
compared to past use (26%), and never use (55%) was associated with more hot flashes, 
(54% current vs 15% past vs 4% never), loss of libido (62% current vs 50% past vs 38% 
never), breast changes (23% current vs 14% past vs 2% never) and fatigue (38% current vs 
23% past vs 16% never) (all comparisons significant p < 0·001) (Figure 4).   
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Discussion  
This large population-based study adds to the literature in this area by examining seven 
disease specific physical symptoms of men of all ages with prostate cancer up to 15 year 
post-diagnosis.  All treatment modalities were included in two countries with high standards 
of services and patient care.  This has allowed us to estimate the population burden of 
physical symptoms as reported by men, their patterns following different treatments and 
their “persistence”.  In light of the uncertainties around optimal treatment from a clinical 
outcome perspective this type of information on patients reported outcomes is potentially 
extremely valuable for informing treatment decision-making. 
 
The burden of symptoms is high with many survivors reporting multiple symptoms.  Nine 
out of ten men reported at least one of the seven possible symptoms at some point post-
diagnosis, and three quarters reported at least one as ‘current’.  However, about one in ten 
survivors reported no symptoms at any time and 25% were currently symptom free.   
 
Over half (57%) reported ‘current’ impotence, almost half (46%) loss of libido and one in six 
‘current’ urinary incontinence, with fatigue a common complaint.  Urinary incontinence and 
impotence were more common post-RP compared to other treatments and bowel problems 
most common post-EBRT.  The pattern of these symptoms was as documented in smaller 
studies reporting on specific treatments. [9, 12, 23-25] However, this study which looks at 
the total population of survivors allows as estimate of total burden.   
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With regard to impotence, men reported current levels of 57% and ever at 68%.  This work 
extends that of Korfage et al, who found that 52 months following treatment, 88% of men 
treated with RP and 64% of those who had EBRT with concurrent HT reported erectile 
dysfunction.[26]   We found similar high levels by examining men up to 15 years post 
diagnosis supporting Korfage’s assertions that erectile dysfunction is likely to be permanent 
if present 12 months or more post-treatment. 
 
The effect of HT in improving survival has been documented, but at a cost of symptoms such 
as loss of libido, fatigue, hot flashes and breast changes.[12,27,28]  Consistent with this, and 
reported for a large cohort, those currently on HT were approximately 10-times more likely 
to report breast changes and hot flashes than those who never had HT. High levels of 
fatigue for those on HT is similar to clinical studies.[29,30]  
 
An important part of our analysis related to the prevalence of symptoms at different times 
since diagnosis.  The lower proportion of bowel problems reported by survivors diagnosed 
≥10 years ago likely reflects lower rates of EBRT in that cohort (confirmed by cancer registry 
data) as well as improvements in technologies. The fact that the proportions who reported 
‘ever’ and ‘current’ symptoms were similar in each survival period, indicates a need for 
ongoing support after PCa treatment. 
 
Implications 
UK guidelines recommend that survivors and their partners are given opportunities to 
discuss psychosexual problems and that counselling on sexual problems and urinary A
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incontinence is available as long as needed.[7] Our results suggest there is likely to be a 
large need  with three quarters of men reporting at least one physical symptom, almost 60% 
current impotence and one in six reporting current incontinence.  
Based on this work, of the 22,823 PCa survivors resident in Ireland at the time of the study, 
we estimate that 17,100±300 had at least one ‘current’ physical symptom; including 
impotence (13,100±400) loss of libido (10,400±400), fatigue (5,000±300) and urinary 
incontinence (3,600±300). Based upon the 2011 Censuses in both countries, we estimate 
that 1.6% of the male population aged 45 and over is a PCa survivor with a ‘current’ physical 
symptom, 1.2% with impotence and 1% loss of libido. This represents a significant number 
of men who require ongoing care. The information in this study could also be used to help 
inform decisions about investigation and treatment of PCa and survivors’ expectation of 
symptoms.[23,31]  Recognition and treatment of physical symptoms should be prioritised in 
patient follow-up. 
 
Strengths 
Unlike other similar patient-reported outcome studies in PCa, this study included men of all 
ages, treated with all available modalities.[31-33] It covered a longer period since 
diagnosis.[9,23] High-quality cancer registries provided the basis for sampling and this 
allowed population representativeness to be assessed and proportions weighted so that 
estimates are of the symptoms burden in the entire survivor population. Self-reported 
treatment was compared with treatment information from each registry; congruence for RP 
was 86% in NI and 70% in RoI, and for EBRT was 96% in NI and 75% in RoI.  Weighting 
allowed us to address some demographic aspects of non-response. A
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Limitations 
As with many questionnaire studies, older persons were less likely to respond but weighted 
proportions allowed adjustment for this.[6] Also, as a cross-sectional study, comparisons 
between groups diagnosed at different time periods have limitations due to changing 
treatment, investigation patterns and different patient profiles.  We recognise that accuracy 
of recall as a potential limitation, for example, the 4% of survivors in the monitoring group 
reporting ‘current’ hot flashes may represent contamination of treatment recall with 
survivors not recognizing that they are having HT.  
 
While we have documented symptoms reported by PCa survivors, we recognise that not all 
can be attributed to PCa treatments. Erectile dysfunction increases with age.[34,35] We 
have reported pre and post  treatment levels of impotence and these increased with age from 16% 
of men under 60, to 18.7% in men aged 60-69 and 20.4% in men aged 70+.  The same men 
responded to post treatment levels of impotence at 66.4% < 60 years, 61.5% 60-69 years, 45.9% 
aged 70+.  These figures reflect the higher rates of radical prostatectomy in younger men and 
monitoring in older men. Urinary incontinence in general male populations, without PCa, has 
been estimated to be between 3 and 11%.[36-37]  Urinary incontinence among the Irish 
population has been reported at 4.5% for men over 50 years, ranging from 2-4% for men 
aged 50-64, 4-7% for  ages 65-74 and 6-11% for those aged over 75 years [38] lower than 
the 16% ongoing incontinence reported post treatment. Some of the reported physical 
symptoms may however be due to co-morbidities, or other treatments e.g. breast changes 
due to commonly used medications.[36,37] Future studies should collect normative data for 
the male population to better determine treatment effects.   A
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In conclusion, physical symptoms following PCa are common, often multiple and persist 
years after diagnosis representing a large health burden.  
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Table 1 - Characteristics of prostate cancer populations: all survivors, random sample, eligible survivors, responders and non-responders 
 
  All survivors  Random  
sample 
Eligible for 
study  
Responders Non-
responders 
Total  N=22,823 N=12,322 N=6,559 N=3,348 N=3,211 
  Number and % of total survivors in each column  
Age at diagnosis 0-59 5,046 (22·1%) 2,039 (16·5%) 1,329 (20·3%) 799 (23·9%) 530 (16·5%) 
60-69 10,212 (44·7%) 4,891 (39·7%)  2,939 (44·8%) 1,631 (48·7%) 1,308 (40·7%) 
70+  7,565 (33·1%)  5,392 (43·8%)  2,291 (34·9%) 918 (27·4%) 1,373 (42·8%) 
Time since 
diagnosis 
2-5 yrs 9,569 (41·9%) 5,340 (43·3%) 3,101 (47·3%) 1,614 (48·2%) 1,487 (46·3%) 
5-9·9 yrs 9,776 (42·8%)  4,324 (35·1%) 2,114 (32·2%) 1,075 (32·1%) 1,039 (32·4%) 
≥10 yrs 3,478 (15·2%) 2,658 (21·6%) 1,344 (20·5%) 659 (19·7%) 685 (21·3%) 
TNM stage* I/II 12,761 (55·9%) 5,792 (47·0%) 3,817 (58·2%) 2,126 (63·5%) 1,691 (52·7%) 
III 2,122 (9·3%) 1,130 (9·2%) 947 (14·4%) 612 (18·3%) 335 (10·4%) 
IV 690 (3·0%) 445 (3·6%) 267 (4·1%) 141 (4·2%) 126 (3·9%) 
Unknow
n 
7,250 (31·8%) 4,955 (40·2%) 1,528 (23·3%) 469 (14·0%) 1,059 (33·0%) 
Gleason grade* 2-4 1,578 (6·9%) 923 (7·5%) 472 (7·2%) 212 (6·3%) 260 (8·1%) 
5-7 11,766 (51·6%) 4,996 (40·5%) 3,609 (55·0%) 2,186 (65·3%) 1,423 (44·3%) 
8-10 2,865 (12·6%) 1,594 (12·9%) 1,060 (16·2%) 625 (18·7%) 435 (13·5%) 
Unknow
n 
6,614 (29·0%) 4,809 (39·0%) 1,418 (21·6%) 325 (9·7%) 1,093 (34·0%) 
*Further information was sourced for TNM stage and Gleason grade for NI responders only. This is reflected in the lower percentage  
with stage unknown among responders compared to the other columns 
 
 
A
cc
ep
te
d 
A
rti
cl
e
 
 
This article is protected by copyright. All rights reserved. 
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, 
which permits use and distribution in any medium, provided the original work is properly cited, the use is non-
commercial and no modifications or adaptations are made. 
 
Table 2 - Characteristics of responders by time since diagnosis 
 
 2-4·9 years post 
diagnosis (n=1,614) 
5-9·9 years post 
diagnosis (n=1,075) 
≥10 years post 
diagnosis (n=659) 
All respondents 
(n=3,348) 
Age at 
diagnosis 
0-59 340 (21·1%) 255 (23·7%) 204 (31·0%) 799 (23·9%) 
60-69 750 (46·5%) 534 (49·7%) 347 (52·7%) 1631 (48·7%) 
70 and over 524 (32·5%) 286 (26·6%) 108 (16·4%) 918 (27·4%) 
Age at 
questionnair
e completion 
0-59 186 (11·5%) 45 (4·2%) 12 (1·8%) 243 (7·3%) 
60-69 637 (39·5%) 346 (32·2%) 102 (15·5%) 1085 (32·4%) 
70 and over 791 (49·0%) 684 (63·6%) 545 (82·7%) 2020 (60·3%) 
Stage Stage I/II 1120 (69·4%) 670 (62·3%) 336 (51·0%) 2126 (63·5%) 
Stage III 323 (20·0%) 183 (17·0%) 106 (16·1%) 612 (18·3%) 
Stage IV 81 (5·0%) 36 (3·3%) 24 (3·6%) 141 (4·2%) 
Unknown 90 (5·6%) 186 (17·3%) 193 (29·3%) 469 (14·0%) 
Gleason 
grade 
Low (2 to 4) 66 (4·1%) 51 (4·7%) 95 (14·4%) 212 (6·3%) 
Intermediate (5 to 7) 1035 (64·1%) 769 (71·5%) 382 (58·0%) 2186 (65·3%) 
High (8 to 10) 356 (22·1%) 170 (15·8%) 99 (15·0%) 625 (18·7%) 
Unknown 157 (9·7%) 85 (7·9%) 83 (12·6%) 325 (9·7%) 
Symptom at 
diagnosis 
Frequency of urine 821 (50·9%) 547 (50·9%) 346 (52·5%) 1714 (51·2%) 
Pain while urinating 103 (6·4%) 88 (8·2%) 65 (9·9%) 256 (7·6%) 
Blood in urine 94 (5·8%) 72 (6·7%) 53 (8·0%) 219 (6·5%) 
Impotence 356 (22·1%) 184 (17·1%) 91 (13·8%) 631 (18·8%) 
Loss of libido 247 (15·3%) 163 (15·2%) 83 (12·6%) 493 (14·7%) 
Back pain 261 (16·2%) 161 (15·0%) 84 (12·7%) 506 (15·1%) 
Primary 
Treatment 
RP 374 (23·2%) 305 (28·4%) 255 (38·7%) 934 (27·9%) 
EBRT with concurrent 
HT 
383 (23·7%) 179 (16·7%) 68 (10·3%) 
630 (18·8%) A
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EBRT without 
concurrent HT 
484 (30·0%) 391 (36·4%) 213 (32·3%) 
1088 (32·5%) 
BT 87 (5·4%) 33 (3·1%) 4 (0·6%) 124 (3·7%) 
HT 147 (9·1%) 91 (8·5%) 72 (10·9%) 310 (9·3%) 
MON 102 (6·3%) 44 (4·1%) 18 (2·7%) 164 (4·9%) 
Missing 34 (2·1%) 31 (2·9%) 28 (4·2%) 93 (2·8%) 
Note: Results not weighted for survey non-response bias. Chemotherapy omitted due to less than 5 respondents. Respondents may have more 
than one symptom. 
RP: Radical prostatectomy, EBRT: External beam radiotherapy, HT: Hormone therapy, BT: Brachytherapy, MON: Monitoring 
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Table 3 - Symptoms (Current and Ever) reported by PCa survivors, by primary treatment modality (weighted for country, age at diagnosis 
and time since diagnosis) 
 
 
RP 
 
EBRT with 
concurrent HT  
EBRT without 
concurrent  HT  
BT  HT 
 
MON  Missing  All Respondents 
Proportion of men reporting symptom (95% CI) 
 
 
Average age at diagnosis(years) 60·5 66·4 67·1 61·7 73·5 67·9 69·0 
 
64.9 
Urinary 
incontinence 
Ever had 
70·3% 
(67·2%, 73·3%) 
24·3% 
(20·8%, 28·0%) 
27·3% 
(24·7%, 3·0%) 
28·5% 
(20·7%, 37·3%) 
21·3% 
(17·1%, 26·1%) 
12·1% 
(7·6%, 18·1%) 
23·5% 
(15·7%, 33·0%) 
37% 
35.4-38.7 
Current 
27·8% 
(24·9%, 30·8%) 
10·7% 
(8·3%, 13·5%) 
11·8% 
(10·0%, 13·9%) 
8·1% 
(4·0%, 14·4%) 
14·5% 
(10·9%, 18·7%) 
6·7% 
(3·4%, 11·6%) 
12·7% 
(7·0%, 20·8%) 
15.8% 
14.6-17.1% 
Loss of libido 
Ever had 
59·5% 
(56·2%, 62·7%) 
74·4% 
(70·6%, 77·9%) 
55·7% 
(52·8%, 58·7%) 
41·5% 
(32·7%, 50·7%) 
58·6% 
(53·1%, 63·9%) 
26·1% 
(19·5%, 33·5%) 
37·3% 
(27·9%, 47·4%) 
57.8% 
56.1%-59.5% 
Current 
47·0% 
(43·7%, 50·3%) 
58·0% 
(53·9%, 62·1%) 
43·1% 
(40·2%, 46·1%) 
26·0% 
(18·5%, 34·7%) 
51·5% 
(46·0%, 56·9%) 
21·8% 
(15·8%, 28·9%) 
29·4% 
(20·8%, 39·3%) 
45.5% 
43.8-47.2% 
Impotence 
Ever had 
87·6% 
(85·3%, 89·7%) 
78·7% 
(75·1%, 81·9%) 
59·6% 
(56·7%, 62·5%) 
58·5% 
(49·3%, 67·3%) 
59·2% 
(53·7%, 64·5%) 
26·1% 
(19·5%, 33·5%) 
42·2% 
(32·4%, 52·3%) 
68.2% 
66.6%-69.8% 
Current 
75·5% 
(72·6%, 78·3%) 
64·2% 
(60·2%, 68·1%) 
50·2% 
(47·2%, 53·1%) 
43·1% 
(34·2%, 52·3%) 
50·9% 
(45·4%, 56·3%) 
20·6% 
(14·7%, 27·6%) 
29·4% 
(20·8%, 39·3%) 
57.2% 
55.5%-58.9% 
Bowel problems 
Ever had 
16·6% 
(14·2%, 19·2%) 
41·0% 
(36·9%, 45·1%) 
33·1% 
(30·4%, 36·0%) 
21·1% 
(14·3%, 29·4%) 
14·2% 
(10·7%, 18·4%) 
3·6% 
(1·3%, 7·7%) 
9·8% 
(4·8%, 17·3%) 
25.5% 
24.1%-27.1% 
Current 
9·2% 
(7·4%, 11·3%) 
22·0% 
(18·7%, 25·6%) 
19·2% 
(16·9%, 21·6%) 
7·3% 
(3·4%, 13·4%) 
9·2% 
(6·3%, 12·8%) 
2·4% 
(0·7%, 6·1%) 
4·9% 
(1·6%, 11·1%) 
14.2% 
13.1%-15.5% 
Breast changes 
Ever had 
6·2% 
(4·7%, 8·0%) 
39·6% 
(35·6%, 43·7%) 
17·7% 
(15·5%, 20·0%) 
1·6% 
(0·2%, 5·8%) 
22·8% 
(18·4%, 27·6%) 
2·4% 
(0·7%, 6·1%) 
4·9% 
(1·6%, 11·1%) 
17.2% 
16.0%-18.6% 
Current 
3·1% 
(2·1%, 4·5%) 
20·0% 
(16·8%, 23·5%) 
8·7% 
(7·1%, 10·4%) 
1·6% 
(0·2%, 5·8%) 
17·8% 
(13·8%, 22·3%) 
1·8% 
(0·4%, 5·2%) 
1·0% 
(0·0%, 5·3%) 
9.3% 
8.3%-10.3% 
Hot flashes Ever had 
15·7% 
(13·4%, 18·3%) 
79·9% 
(76·4%, 83·1%) 
40·4% 
(37·5%, 43·3%) 
11·4% 
(6·4%, 18·4%) 
60·1% 
(54·6%, 65·3%) 
6·1% 
(2·9%, 10·9%) 
5·9% 
(2·2%, 12·4%) 
38.7% 
37.1-40.4% A
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Current 
7·0% 
(5·4%, 8·8%) 
27·7% 
(24·1%, 31·5%) 
14·5% 
(12·5%, 16·7%) 
2·4% 
(0·5%, 7·0%) 
40·5% 
(35·3%, 46·0%) 
3·6% 
(1·3%, 7·7%) 
2·0% 
(0·2%, 6·9%) 
16.0% 
14.8-17.3% 
Fatigue 
  
Ever had 
50·4% 
(47·1%, 53·7%) 
74·0% 
(70·2%, 77·5%) 
63·4% 
(60·5%, 66·2%) 
44·7% 
(35·7%, 53·9%) 
42·0% 
(36·7%, 47·5%) 
8·5% 
(4·7%, 13·8%) 
18·6% 
(11·6%, 27·6%) 
54.9% 
53.2-56.6% 
Current 
18·1% 
(15·6%, 20·7%) 
31·5% 
(27·7%, 35·4%) 
22·8% 
(20·4%, 25·3%) 
13·0% 
(7·6%, 20·3%) 
28·4% 
(23·7%, 33·5%) 
4·2% 
(1·7%, 8·5%) 
4·9% 
(1·6%, 11·1%) 
21.7% 
20.3-23.2% 
No symptom 
Ever had 
4·3% 
(3·1%, 5·9%) 
1·2% 
(0·5%, 2·5%) 
9·6% 
(8·0%, 11·5%) 
17·1% 
(10·9%, 24·9%) 
10·9% 
(7·8%, 14·8%) 
58·2% 
(50·3%, 65·8%) 
37·3% 
(27·9%, 47·4%) 
10.4% 
9.4-11.4 
Current 
15·5% 
(13·2%, 18·0%) 
16·5% 
(13·6%, 19·8%) 
29·4% 
(26·8%, 32·2%) 
41·5% 
(32·7%, 50·7%) 
19·5% 
(15·4%, 24·2%) 
63·6% 
(55·8%, 71·0%) 
49·0% 
(39·0%, 59·1%) 
25.2% 
23.7-26.7% 
Any symptom  
Ever had 
95·7% 
(94·1%, 96·9%) 
98·8% 
(97·5%, 99·5%) 
90·4% 
(88·5%,92·0%) 
82·9% 
(75·1%, 89·1%) 
89·1% 
(85·2%, 92·2%) 
41·8% 
(34·2%, 49·7%) 
62·7% 
(52·6%, 72·1%) 
89.6% 
88.6-90.6 
Current 
84·5% 
(82·0%, 86·8%) 
83·5% 
(80·2%, 86·4%) 
70·6% 
(67·8%, 73·2%) 
58·5% 
(49·3%, 67·3%) 
80·5% 
(75·8%, 84·6%) 
36·4% 
(29·0%, 44·2%) 
51·0% 
(40·9%, 61·0%) 
74.8% 
73.3-76.3% 
Note: Results were weighted for survey non-response bias· Chemotherapy omitted due to less than 5 respondents· Respondents may have 
more than one symptom· 
RP: Radical prostatectomy, EBRT: External beam radiotherapy, HT: Hormone therapy, BT: Brachytherapy, MON: Monitoring  
CI: Confidence interval 
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Figure 1 - Recruitment of prostate cancer survivors  
 
 
 
 
 
After randomisation 12,322 PCa survivors were screened for eligibility to participate  
6,559 (53.2%) survivors eligible to be sent questionnaire  
297 (4.5%) Ineligible following questionnaire 
despatch and removed from denominator 
92 (1·4%) cognition/ other health problems 
67 (1·0%) Patient deceased 
44 (0·7%) Patient unaware of diagnosis 
94 (1·4%) Incorrect address/gone away 
 
Overall adjusted response   
rate = 54%       (3,348/6,262) 
 
Total Sampling Frame 
PCa survivors in RoI and NI 1/1/95 to 31/3/2010  
(RoI N=17,304; NI N=5,519) 
5,763 (46.8%) excluded following eligibility screening  
1,724 (14·0%) Clinical non-response/clinical refusal/inactive GP/ Patient changed 
GP 
594 (4·8%) Cognition/other health problems 
503 (4·1%) Patient deceased 
362 (2·8%) Patient unaware of diagnosis 
127 (1·0%) GP unaware of diagnosis/unconfirmed diagnosis 
286 (2·3%) Other health problems reported by GP (NI only) 
2,167 (17·6%) Other 
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Figure 2a: ‘Current’ impotence, incontinence and bowel problem           Figure 2b: ‘Current’ 
loss of libido, breast changes, fatigue and hot                   
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Figure 3a - Impotence pre treatment and currently                                      Figure 3b - Loss of 
Libido pre treatment and currently 
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All = all patients, RP = radical prostatectomy, EBRT = External Beam Radiotherapy, HT = Hormone Therapy 
 
Note: Only impotence and loss of libido are compared pre- and post-treatment as definitions for other conditions differed 
pre and post treatment.
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Figure 4 - Current symptoms reported by prostate cancer survivors by hormone therapy 
utilisation 
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